• Imagine


    we could save lives
    Every year more than 8,000,000 people die from sepsis worldwide

About us

Company profile

Adrenomed AG is a privately-financed biopharmaceutical company with a clear mission: to lower sepsis mortality. Adrenomed was established in 2009 by Dr. Bernd Wegener and Dr. Andreas Bergmann, co-founders & former executive managers of BRAHMS AG. They changed the standard of care in sepsis by developing the biomarker Procalcitonin (B.R.A.H.M.S. PCTTM), the diagnostic gold standard in sepsis management.

We are focusing on the discovery and development of monoclonal antibody therapies that target the vasoactive Adrenomedullin system as a new strategy for causative and safe treatment of acute circulatory breakdoan, e.g. septic shock. Our company’s lead product is the new first-in-class drug candidate Adrecizumab, a humanized monoclonal antibody against Adrenomedullin. Adrenomedullin is a vasoactive peptide hormone released by vascular endothelial cells. During sepsis, the perturbation of the endothelial integrity leads to collapse of blood pressure and septic shock which frequently results in multiple organ failure and death. Adrenomedullin is a key regulator of blood pressure and plays a pivotal role in the development of septic shock. Adrecizumab has an innovative mode of action that controls Adrenomedullin activity and stabilizes the circulation in sepsis, leading to lower mortality.


Board of Directors

Dr. Bernd Wegener | Chief Executive Officer (CEO)

Dr. Andreas Bergmann  | Chief Scientific Officer (CSO)

Bernd Wegener and Andreas Bergmann were both founders and managers of BRAHMS AG. BRAHMS AG developed the sepsis marker Procalcitonin and created a new diagnostic standard of care in sepsis management.


Senior Management

The virtual nature of the company leads to a very lean personnel structure that mainly focusses on project management. The key competences for planning and evaluation of the preclinical and clinical study program as well as CMC development are in-house capabilities; all operational resources are third party based capacities. The experienced sepsis research for decades resulted in an extensive network with key opinion leaders in sepsis therapy worldwide that support Adrenomed’s clinical research.

Prof. Paul Scigalla | Chief Medical Officer (CMO)

Dr. Frauke Hein | Chief Business Officer (CBO)

Dr. Joachim Struck | Head of Research & Development


Regulatory Consultants

Granzer Regulatory Consulting & Services


Supervisory Board

Renke Lührs (Chairman) | Corporate Lawyer & Partner of Buse Heberer Fromm Rechtsanwälte Steuerberater Partnerschaftsgesellschaft in Berlin

Dr. Gerald Moeller | Co-founder of Adrenomed with over 35 years of Management Experience in the Diagnostic and Pharmaceutical Industry

Dr. Metod Miklus | CEO of ExpoCapital GmbH and Co-founder of BRAHMS



  • Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure

Alexandre Mebazaa, Pierre François Laterre, James A. Russell, Andreas Bergmann, Luciano Gattinoni, Etienne Gayat, Michael O. Harhay, Oliver Hartmann, Frauke Hein, Anne Louise Kjolbye, Matthieu Legrand, Roger J. Lewis, John C. Marshall, Gernot Marx, Peter Radermacher, Mathias Schroedter, Paul Scigalla, Wendy Gattis Stough, Joachim Struck, Greet Van den Berghe, Mehmet Birhan Yilmaz and Derek C. Angus, IJournal of Intensive Care 2016, 4:24 PDF | PubMed

  • Epitope specificity of anti-Adrenomedullin antibodies determines efficacy of mortality reduction in a cecal ligation and puncture mouse model

Joachim Struck, Frauke Hein, Siegmund Karasch, Andreas Bergmann, Intensive Care Medicine Experimental 2013, 1:3 PDF | PubMed

  • Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock

Katja Wagner, Ulrich Wachter, Josef A Vogt, Angelika Scheuerle, Oscar McCook, Sandra Weber, Michael Gröger, Bettina Stahl, Michael Georgieff, Peter Möller, Andreas Bergmann, Frauke Hein, Enrico Calzia, Peter Radermacher, Florian Wagner, Intensive Care Medicine Experimental 2013, 1:2 | PDF | PubMed

  • Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis

Rossella Marino, Joachim Struck, Alan S Maisel, Laura Magrini, Andreas Bergmann and Salvatore Di Somma, Critical Care 2014, 18(1):R34 | PDF | PubMed

  • Hemodynamics effects of Adrecizumab in sepsis rat

Blet A, Sadoune M , Polidano E , Merval R, Bernard C , Samuel JL and Mebazaa A, Intensive Care Medicine Experimental, 2015, 3(Suppl 1):A618 | PDF

  • Endothelial Barrier Injury is directly related to Kidney Dysfunction in resuscitated murine shock model

Zink F, Stenzel T, Wachter U, Vogt J, McCook O, Radermacher P.,  Shock 2015, 44 Suppl 2:15-6. | Website | F1000Prime

  • Adrenomedullin: it's double-edged sword during sepsis slices yet again

Kox M, Pickkers P, (Editorial) Intensive Care Medicine Experimental, 2014, 2:1 | PDF

  • Sepsis bekämpfen - Leben retten

Andreas Bergmann in |transkript 3/2016 | Website (german)


  1. Angus et al. (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36(2): 222-231.
  2. U.S. National Hospital Discharge Survey (2008) www.cdc.gov
  3. Kitamura et al. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun, 192: 553-60.
  4. Nishio et al. (1997) Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med, 25(6): 953-7.
  5. Ueda et al. (1999) Increased Plasma Levels of Adrenomedullin in Patients with Systemic Inflammatory Response Syndrome. Am J Respir Crit Care Med, 160: 132-6.
  6. Sato et al. (1995) Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Sci, 57(2): 189-94.
  7. Wagner et al. (2012) Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock, Intensive Care Medicine Experimental, 1:2.
  8. Karpinich et al. (2011) Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models. Curr Hypertens Rev, 7(4):228-239.